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aBsTracT
The current state of evidence in non-pharmacological treatments amounts to an impending paradigm shift in neurology where physicians 
should be alerted that some rehabilitation interventions are already supported in current therapeutic guidelines. This manuscript aims to 
overview the best scientific data supporting referral to rehabilitation services in order to help physicians make the best use of the existing 
evidence for non-pharmacological treatments in the different stages of Parkinson´s disease. 
Keywords: Parkinson’s disease, non-pharmacological treatments, physical therapy, speech therapy, rehabilitation.
resUMo
O atual nível de evidência para tratamentos não farmacológicos sugere uma mudança de paradigma na área da neurologia, a qual passa 
por alertar os médicos neurologistas de que algumas intervenções na área da reabilitação estão já fundamentadas em linhas de orientação 
terapêutica. Este trabalho tem o objetivo de rever a melhor evidencia cientifica para a definição de critérios de encaminhamento para servi-
ços de reabilitação, procurando auxiliar os médicos neurologistas a obter o melhor beneficio da evidência cientifica atual para tratamentos 
não farmacológicos nos diferentes estadios da doença de Parkinson. 
Palavras-chave: doença de Parkinson, tratamentos não farmacológicos, fisioterapia, fonoaudiologia, reabilitação.
Parkinson’s disease (PD) is a complex heterogeneous neu-
rodegenerative disorder. While many pharmacological treat-
ments in PD have proven beneficial, some motor and non-
motor problems associated with disease progression are not 
always most comprehensively addressed by a purely pharma-
cological approach, such as freezing of gait or postural insta-
bility The current gold standard drug for symptomatic treat-
ment of motor symptoms of PD, levodopa, has limitations in 
its use1,2 which has justified the need for adjunctive treatment 
for dopaminergic-responsive symptoms and new treatments 
for non dopaminergic-related symptoms. 
Current PD guidelines already recognize the potential 
role of some rehabilitation interventions as a mean to im-
prove patients’ functionality and to help patients and their 
families to cope with the disability and functional limita-
tions due to PD3-6. As for example, the Quality Measurement 
and Reporting Subcommittee of the American Academy of 
Neurology recently proposed a set of quality measures for 
neurology practice7 that consider PD rehabilitative therapy 
options as a quality measure for PD care, recommending it to 
be addressed by clinicians in clinical practice.
In contrast to these findings, current referral rates to re-
habilitation interventions in PD are clearly low8. As repor-
ted by Nijkrake and colleagues8, only 63% of the PD patients 
were referred to physical therapy for problems with gait, pos-
ture, transfers and balance. For problems with speech, voice, 
eating and drooling, only 14% of the patients were referred 
to speech therapy. For problems related to arm and hand ac-
tivities, gait, transfers, balance, posture, leisure activities, per-
sonal care and domestic/work activities, only 9% of the PD 
patients were referred to occupational therapy. Numerous 
barriers for referral have been discussed in the literature, such 
as: the degree of the physician’s perceived benefit of rehabili-
tation in PD, the physician’s lack of awareness of the recently 
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available supportive data, the lack of clear indications for 
non-pharmacological care and/or the lack of proper time al-
located to screen for these referrals8.
This justifies the need for a better definition of rigorous, 
up-dated and feasible medical indications for referral to reha-
bilitation services interventions that may be applied in an in-
tegrated systematic manner and allow better evaluation and 
monitoring of its true effectiveness in different stages of PD. 
We believe that such data needs to be translated into 
practical and easy to implement recommendations clari fying 
which patients are appropriate for referral, when referrals 
should begin and what type of problems should be addressed 
and for how long. In addition, specific interventions should 
be identified based on the evidence for efficacy and safety. It 
is also important to provide clear guidance about what type 
of improvements should be expected from interventions and 
how will those gains be expected to be maintained. 
Hence, the objective of this short opinion statement was 
to overview the indications for referral of PD patients to re-
habilitation services based on a review of the recommenda-
tions of current published PD international guidelines and 
published systematic reviews regarding non-pharmacologi-
cal and non-surgical treatments in PD. 
MeThod
We reviewed the following evidence-based PD recommen-
dations and guidelines: European Federation of Neurological 
Societies and Movement Disorder Society (EFNS/MDS-ES)3, 
National Institute for Health and Clinical Excellence (NICE)4, 
American Academy of Neurology (AAN)5 and Movement 
Disorder Society (MDS)6, concerning non-pharmacological 
and non-surgical interventions. These were believed to offer 
an exhaustive, synthetic and up-to-date analysis of the level of 
evidence of all treatments proposed for PD. As a second step, 
we reviewed published Cochrane Collaboration and other 
systematic reviews and other key clinical studies focu sing on 
the effectiveness of similar interventions in PD. Based on the 
level of evidence and grade of recommendations supporting 
the different rehabilitation interventions, we then outlined po-
tential medical referral indications. In order to support which 
patients are more appropriate for referral, we structured po-
tential medical referral indications based on a disease-specific 
problem for which there is some evidence that these may have 
some benefit with non-pharmacological treatments, and, thus, 
with a relative contribution to the appropriateness of referral.
resULTs
The non-pharmacological treatment interventions most 
frequently highlighted in all PD guidelines are provided by 
physical therapists, speech-language therapists, PD nurse 
specialists and occupational therapists (Table 1). In Tables 
2 and 3 we show the referral indications for non-pharma-
cological and non-surgical therapies, based on specific di-
sease problems in PD. We chose 7 motor problem domains 
(transfers, gait, physical capacity, postural instability, falls, 
freezing and speech) and 7 non-motor problem domains 
(orthostatic hypotension, urinary disturbance, gastrointes-
tinal motility dysphagia, drooling, sleep disorders, and pain) 
as indications for referral.
From the data analyzed in our review it is possible to 
conclude that there is: 1) consistent data supporting physi-
cal therapy referral and use in PD for transfers and mobility 
problems, gait disturbances, balance, falls and freezing; and 
2) a possible beneficial role of speech therapy for vocal inten-
sity, phonation and dysphagia. 
Given the problem-based distribution of the evidence, it 
is important to note that even though not included in the 
table, there is some evidence for the benefit of a PD nurse 
specialist for general counselling and palliative care9 and 
there is insufficient data to conclude on the role of occupa-
tional therapy and complementary therapies. Additionally, 
there is also a small amount of consensual general measures 
existing for most non-motor problems in PD and no strong 
data on rehabilitation interventions for parkinso nism and 
motor complications. 
Translation of evidence-based data to  
clinical practice
Increased clinicians awareness about the benefits of 
re habilitation and initiatives to overcome barriers to re-
ferral are critical to improve the quality of care of people 
with PD.
Table 1. Summary of non-pharmacological therapies outlined 
in the reviewed guidelines.
 Non-pharmacological therapies
Main key therapies 
Nurse PD specialist
Physical therapy 







Complementary therapies such as: Tai Chi, Quigong, Massage, 
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Adequate screening and selection of these patients for 
non pharmacological treatments may increase the benefits of 
these treatments, and reduce unnecessary procedures and un-
realistic expectations in patients with a less favoura ble profile. 
Given the practical limitations in a general neurological setting, 
we faced the challenge to translate the exis ting evidence into 
concise and easily applicable referral indications, embedded in 
a user-friendly referral support tool (Table 2 and 3).
We now address below 3 important questions regarding 
referral of patients to rehabilitation interventions: 
Table 2. Summary of suggested non-pharmacological, non-surgical referral indications based on specific motor problem/
impairment domains in Parkinson’s disease.
Motor problems
Problem domain Treatment interventions Guidelines and level of evidence Implications for referral
Transfers
& Mobility Problems
Strategy training with cueing. KNGF [11] – Level II Physical therapy should be 
considered to address motor 
impairments in transfers & mobility.
MDS [6] – Level II
Cognitive movement strategy training 
for daily activities and transfers.
KNGF [11] – Level II 
Movement initiation training. NICE [4] – Level II 
Training functional independence, 
including mobility and activities of daily 
living.
NICE [4] – Level II 
Alexandre Technique. NICE [4] – Level III
Advice regarding safety in the home 
environment.
NICE [4] – Level II 
Gait disturbances Gait re-education. NICE [4] – Level II Physical therapy should be 
considered to address motor 
impairments in balance, gait, 
physical capacity, falls and freezing.
Tai chi and Qigong may be considered 
for balance and gait impairments.
Cued training and strategies. EFNS/ MDS [3] – Level II 
Cued training for dual task. EFNS/ MDS [3] – Level III 
Treadmill training for gait speed. EFNS/ MDS [3] – Level II 
Exercise - based interventions. EFNS/ MDS [3] – Level II 
Physical capacity  Aerobic exercise. NICE [4] – Level II 
EFNS/ MDS [3] – Level II
Postural instability and 
balance problems
Treadmill training.  MDS [6] – Level II 
EFNS/ MDS [3] – Level II
Physical activity and exercise. MDS [6] – Level II 
EFNS/ MDS [3] – Level II
Balance training. NICE [4] – Level II 
Tai Chi or Qigong. EFNS/ MDS [3] – Level II 
Falls and fear of falling General elderly recommendations. EFNS/ MDS [3] – Level IV
Physical activity and exercise for near 
falls.
MDS [6] – Level II 
EFNS/ MDS [3] – Level II
Physical activity and exercise for falls. MDS [6] – Level III 
EFNS/ MDS [3] – Level II
Freezing Cueing training in the home. MDS [6] – Level II Physical therapy should be 
considered for cueing training for 
freezing.
EFNS/ MDS [3] – Level II
Visual or auditory cues MDS [6] – Level III 
EFNS/ MDS [3] – Level III
Combining treadmill training and 
cueing.
MDS [6] – Level II 
EFNS/ MDS [3] - Level II
Speech impairment Lee Silverman Voice Therapy (LSVT). NICE [4] – Level II Speech therapy using LSVT may 
be considered to address motor 
complications regarding vocal 
intensity and phonation of speech.
MDS [6] – Level II
EFNS/ MDS [3] – Level II
Pitch Limiting Voice Treatment (PLVT) MDS [6] – Level IV
EFNS/ MDS [3] – Level IV
Teaching strategies to optimise speech 
intelligibility.
NICE [4] – Level IV
Use of assistive technologies. NICE [4] – Level IV
The evidence was graded according to original source. However, to facilitate interpretation and comparison we convert NICE guideline recommendations to level 
of evidence, based on the following: Class A=Level I; Class B=Level II; Class C=Level III; Class D (GPP)=Level IV. Abbreviations: EFNS/MDS-ES, European Federation 
of Neurological Societies and Movement Disorder Society; NICE, National Institute for Health and Clinical Excellence; MDS, Movement Disorder Society.
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Which patients to refer?
Here we argue that a rationale that allows us to answer 
the question which patients to refer should be based on the 
symptom or problem the patient has and the effectiveness of 
the alternative treatments for that specific problem. 
Hence, according to the specific disease problems, peo-
ple with PD that experience problems with transfers, pos-
ture, reaching and grasping, gait, freezing, falls and physi-
cal capa city should be referred to a physiotherapist. This is 
in line with current practice recommendations supported in 
a recent evidence-based analysis of physical therapy in PD10 
and two specific physical therapy PD guidelines11,12. People 
with PD that experience problems in vocal intensity, pho-
nation and dysphagia may be referred to a speech therapist. 
Additionally, with less supporting evidence, people with PD 
that expe rience balance and gait impairments may benefit 
from Tai Chi and Qigong3.
It is important to recognize that the evidence in all cur-
rent guidelines regarding non-pharmacological, non surgical 
treatments supporting the interventions applied to each im-
pairment differ broadly and are limited, in large part due to 
the methodological flaws of the available studies. This makes 
it difficult to interpret and conclude on the specific charac-
terization of each problem and which patients respond bet-
ter to a given treatment. 
Additionally, the severity of cognitive impairment may 
have a negative impact on the appropriateness of referral. 
One may believe that patients who exhibit cognitive impair-
ment may be less favourable due to a decreased ability to 
coo perate with the treatment. Conversely, they are usually 
excluded from research studies13 and so current findings can 
not yet be generalised to these patients.
When to refer?
Concerning early stages of the disease, according to the 
physical therapy international guideline11, physical therapy 
is the only non-pharmacological treatment intervention that 
explicitly recommends that standard medical care should be 
complemented with early referral to physiotherapy servi ces in 
the early to intermediate stages of PD. However, it is not clear 
for what specific problem and with what expected outcome.
Most studies focus on patients in intermediate stages of 
the disease (stages II and III on the Hoehn and Yahr Scale). 
For example, daily activities and transfers were shown to 
improve with movement strategy training using exter-
nal and cognitive cues in a 2-week inpatient rehabilitation 
program14 with 33 PD patients in stage II or III Hoehn and 
Yahr, declining after 3 months without training after dis-
charge. Combining strength, gait, treadmill and relaxation in 
a six week group physical therapy was also shown to induce 
Table 3. Summary of suggested non-pharmacological, non-surgical referral indications based on specific non-motor problem/
impairment domains in Parkinson’s disease.
Non motor problems
Problem domain Treatment interventions Guidelines and level of evidence Implications for referral
Orthostatic 
hypotension
 General recommendations. MDS [6] – Level IV General measures may be addressed 
by any of the multidisciplinary team 
members for non-motor problems such 
as orthostatic hypotension, nocturia, 
constipation, daytime somnolence, REM 
sleep behaviour disorder and good sleep 
hygiene.
EFNS/ MDS [3] – Level IV
Urinary disturbance General measures for treating nocturia. MDS [6] – Level IV
EFNS/ MDS [3] – Level IV
Gastrointestinal 
motility
General recommendations for 
constipation.
MDS [6] – Level IV
EFNS/ MDS [3] – Level IV
Dysphagia Speech therapy for assessment, 
swallowing advice and further 
instrumental investigations.
MDS [6] – Level IV Speech therapy for assessment and 
swallowing advice may be considered for 
dysphasia and drooling.
Advice on modification of food/drink. EFNS/ MDS [3] – Level IV
Management to support safety and 
efficiency of swallowing and minimize 
risk of aspiration.
NICE [4] – Level IV
Excessive saliva and 
drooling
Behavioral management techniques. NICE [4] – Level IV
 Sleep disorders General measures for treatment of 
daytime somnolence in PD.
NICE [4] – Level IV General measures may be addressed 
by any of the multidisciplinary team 
members for non-motor problems such 
as daytime somnolence, REM sleep 
behaviour disorder, good sleep hygiene 
and pain.
MDS [6] – Level IV
In REM sleep behaviour disorder in PD, 
methods of self-protection.
MDS [6] – Level IV
Good sleep hygiene. NICE [4] – Level IV
MDS [6] – Level IV
Pain Generic management. NICE [4] – Level IV
The evidence was graded according to original source. However, to facilitate interpretation and comparison we convert NICE guideline recommendations to 
level of evidence, based on the following: Class A=Level I; Class B=Level II; Class C=Level III; Class D (GPP)=Level IV. Abbreviations: EFNS/MDS-ES, European 
Federation of Neurological Societies and Movement Disorder Society; NICE, National Institute for Health and Clinical Excellence; MDS, Movement Disorder 
Society.
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changes in UPDRS-III, Sickness Impact Profile and timed 
comfortable walking speed in a single-blind, cross-over, RCT 
in 68 PD patients in stage II or III Hoehn and Yahr15. Similar 
beneficial changes in UPDRS-III were obtained in a physi-
cal therapy program named BIG with a four week individual 
training of large amplitude movements in 60 patients in I to 
III Hoehn and Yahr16.
Difficulty in mobility activities, gait disturbances, postu-
ral instability, freezing, falls and speech impairment emerge 
as disease progresses and occur mainly in advanced stages 
of PD17. This stage is commonly defined as stages 4 and 5 
on the Hoehn and Yahr scale, which corresponds to loss of 
physical independence18. Thus, it is reasonable to believe 
that referral for physiotherapy interventions would largely 
be focused in this advanced PD stage. Interestingly, most 
rehabilitation clinical trials generally exclude patients in 
this advanced PD stage with a mean upper age limit for 
exclusion of 79.3 years19. Indeed, to our knowledge, there 
are no RCTs that have objectively assessed the efficacy 
and safety of these non-pharmacological treatments in ad-
vanced stages PD. It has only been reported that referral to 
a nurse specialist may be be neficial in particular in the pal-
liative stage for management of drugs, pressure ulcer risk 
and ongoing education4. This limits the amount and quality 
of data for referral on current non pharmacological inter-
ventions for motor and non motor problems in PD in this 
stage. It also limits the application of our proposed refer-
ral indications to advanced stages PD and, thus, should be 
considered with care. 
To what end? 
The specific therapeutic interventions outlined in the 
guidelines are briefly summarized in Table 2 and 3. Im -
portantly, there is a common perception that none of the cur-
rently available therapeutic interventions, alone or combined 
with other interventions, offers an entirely satisfying strategy 
for managing PD because patients suffer from multiple pro-
blems. However, regarding rehabilitation interventions, they 
usually require compatible and even similar therapeutic in-
terventions (Figure). Consequently, the combination of these 
therapeutic interventions outlined in the literature should 
be evaluated. It is necessary to see if and how the interven-
tions are related or interplay and then try developing a refer-
ral treatment approach that combines interventions based 
on a solid rationale of the interplay of their true effectiveness, 
safety and health care contexts and costs.
Figure. Intersection of non-pharmacological treatment interventions for Parkinson’s disease. Some motor problems may have 
similar therapeutic interventions. For example, treadmill training may be used for problems such as gait, freezing, postural 
instability and fear of falling. The combination of these therapeutic interventions may allow us to see how the interventions are 





Tai Chi and Oigong
Treadmill training
Physical activity and exercise
Cued training for dual task
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Safety issues should also be considered for referral. Ideally, 
there should be a balance between efficacy, safety and useful-
ness of a given intervention in order to be considered clini-
cally useful and recommend for referral. However, regarding 
safety it has only been reported concerns on potential ad-
verse effects of cueing-based gait training but it was shown 
not to increase the risk of falling20. Similarly, there has also 
been concerns of the possible adverse effects of nutritional 
supplements and its influence on antiparkinsonian medica-
tion3. Additionally, the EFNS/MDS-ES guidelines3 highlights 
that the degree of specific expertise among physical thera-
pists allows better intervention on issues of safety and pre-
vention of falls/injuries while promoting mobility and main-
taining optimal levels of physical activity10,13. 
implications for clinical practice
Addressing non-pharmacological interventions and their 
potential use on daily routine should be a standard part of the 
medical treatment of patients with PD. According to inclu ded 
guidelines/recommendations and systematic reviews, at this 
time, there is enough evidence for physicians to refer or recom-
mend physical therapy, some evidence for speech, less for a PD 
nurse specialist, and no evidence for occupational therapy. 
implications for clinical research
More strong clinical data supporting the real efficacy and 
safety of non-pharmacological interventions in all stages PD 
remains an unmet need. The combination of these treat-
ments and their application in an integrated and systematic 
manner is also of interest for future studies.
In addition, variation in rehabilitation referral may be in-
dicative of problems with access and/or inappropriate re-
ferral. An understanding of the factors that affect physician/
neuro logist referral to rehabilitation is important because of 
the influence referrals can have on the costs and quality of 
medical care. There is also a strong need for long term ana-
lysis of these interventions on motor and non-motor pro-
blems with well designed RCTs in order to allow us to con-
clude on true efficacy, on the optimal timing, on safety and 
on stage for referral.
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